Abstract:Background Doxorubicin (DOX) is a breakthrough drug in cancer therapy that mediates irreversible dosedependent cardiotoxicity with poor outcomes.Cardiomyocyte ferroptosis plays a pivotal role in the progression of DOX-induced cardiomyopathy (DIC). Agents that block DOX-induced cardiomyocyte ferroptosis may have clinical utility in the treatment of DIC. Purpose We pursued the potential role of protosappanin A (PrA), an active constituent extract from traditional Chinese hematoxylin, on DOX-induced cardiac dysfunction. Methods We established acute DIC murine models to investigate the role of PrA in DOX-induced cardiotoxicity.In vivo, western blotting was performed to assess the levels of classical proteins associated with the iron death pathway, while Prussian blue staining and DHE staining were utilized to measure iron ion levels and reactive oxygen species respectively. In vitro, DOX-induced H9C2 cells model was established and the level of ferroptosis-related indicators were detected,such as iron, reactive oxygen species (ROS), and lipid peroxides. Proteome microarray, Molecular docking and Cellular thermal shift assay were used to identify the molecular targets (ACSL4 and FTH1) of PrA. Pull-down assay was used to validate the interaction of PrA with ACSL4 and FTH1 proteins in lysates from H9c2 cells, and explored theirs possible mechanism of action. Finally, we investigated the in vivo effect of PrA treatment in mice challenged with a myocardial ischemia-reperfusion mouse model. Results We report for the first time that PrA ameliorates myocardial damage and cardiac dysfunction in a mouse model of DIC. PrA improves DOX-induced ferroptotic phenotypes in cardiomyocytes, as demonstrated by reduced production of iron, reactive oxygen species (ROS), and lipid peroxides, thereby preserving mitochondrial homeostasis. PrA physically combines with the ferroptosis-related protein acyl-CoA synthetase long-chain family member 4 (ACSL4) and ferritin heavy chain 1 (FTH1), thus conferring the following regulatory mechanisms: PrA inhibits ACSL4 phosphorylation and subsequent phospholipid peroxidation; PrA prevents FTH1 autophagic degradation and subsequent ferrous ions (Fe2+) release. Notably, the cardioprotective and antiferroptotic activities of PrA are verified in a myocardial ischemiareperfusion mouse model. Conclusion Our studies indicate for the first time that PrA has a superior protective effect against DOX-induced cardiotoxicity via inhibiting a dual ferroptosis-assistance mechanism of the ACSL4/FTH1-dependent axis. We unveil a novel pharmacological inhibitor that targets ferroptosis, highlighting additional therapeutic options for chemodrug-induced cardiotoxicity and ferroptosis-triggered disorders.

Lipid discovered in American ginseng alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocyte ferroptosis

Network-driven Targeted Analysis Reveals That Astragali Radix Alleviates Doxorubicin-Induced Cardiotoxicity by Maintaining Fatty Acid Homeostasis.

Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt/mTOR signaling pathway to prevent Doxorubicin-induced cardiotoxicity

Asiatic acid ameliorates doxorubicin-induced cardiotoxicity by promoting FPN-mediated iron export and inhibiting ferroptosis

Ferruginol Restores SIRT1-PGC-1α-Mediated Mitochondrial Biogenesis and Fatty Acid Oxidation for the Treatment of DOX-Induced Cardiotoxicity

Galangin alleviated Doxorubicin-induced cardiotoxicity by inhibiting ferroptosis through GSTP1/JNK pathway

Fucoidan alleviates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via Nrf2/GPX4 pathway

Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling

Revealment study on the regulation of lipid metabolism by Lingguizhugan Decoction in heart failure treatment based on integrated lipidomics and proteomics

Licochalcone A alleviates ferroptosis in doxorubicin-induced cardiotoxicity via the PI3K/AKT/MDM2/p53 pathway

Ling-Gui-Zhu-Gan decoction protects against doxorubicin-induced myocardial injury by downregulating ferroptosis

Glabridin Prevents Doxorubicin-Induced Cardiotoxicity Through Gut Microbiota Modulation and Colonic Macrophage Polarization in Mice

Red ginseng prevents doxorubicin-induced cardiomyopathy by inhibiting cell death via activating the Nrf2 pathway

Identification of key pharmacodynamic markers of American ginseng against heart failure based on metabolomics and zebrafish model

Liquiritigenin alleviates doxorubicin-induced chronic heart failure via promoting ARHGAP18 and suppressing RhoA/ROCK1 pathway

Ginsenoside Rb1 attenuates doxorubicin induced cardiotoxicity by suppressing autophagy and ferroptosis

Prevention of Free Fatty Acids/high Fat Diet‐induced Hepatic Lipotoxicity by 18β Glycyrrhetinic Acid

Glycnsisitin A: A promising bicyclic peptide against heart failure that facilitates TFRC-mediated uptake of iron in cardiomyocytes

Prevention of Free Fatty Acid-Induced Hepatic Lipotoxicity by 18Beta-Glycyrrhetinic Acid Through Lysosomal and Mitochondrial Pathways.

Protosappanin a protects DOX-induced myocardial injury and cardiac dysfunction by targeting ACSL4/FTH1 axis-dependent ferroptosis

Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway